Dr Ado Mohammed, a Nigerian who owns a contract research organisation with branches in Nigeria, US and UK, noted during the 1st clinical trial summit that held in Lagos between the 15th and 16th of September 2012 that Nigeria is a potential clinical trial destination route. While many other presenters at the meeting discussed extensively about the challenges and obstacles there are to the conduct of good quality research in Nigeria, Dr Ado spent 40 minutes of his lecture session sharing with the over 70 participants at the conference, the large potentials there are in Nigeria for the conduct of clinical trials.

For one, the huge population of Nigeria is a great asset, he notes. Clinical researchers would rather conduct clinical trials in a single country that run trials in multiple countries. Nigeria large and diverse populations, large number of people who do not abuse drugs, large number of hospitals which can serve as points for recruitment of clinical trial participants, large number of highly skilled health care practitioners, an organised clinical regulatory system, efficient courier services, transport systems and communication networks, and registered clinical trial support services. These are all incredible assets the country should celebrate.

Dr Mohammed notes that he his not unaware of the many challenges in the country. However, these challenges are not peculiar to Nigeria. Pharmaceutical countries are ready to invest hugh resources to resolve these problems researchers can demonstrate their capacity to conduct good clinical trials that would generate world class trial results.

Prof Okoye, the President of the Association of Good Clinical Practice, one of the two organisers of the conference (the conference was organised in collaboration with NAFDAC) noted that clinical trials have the potential to generate more resources than crude oil for Nigeria. She noted that clinical research remains one of the top five national sources of income for Nigeria.

Despite the attractiveness of clinical trials, it is important to ensure and prevent the potential for abuse and exploitation. Mr Aminu Yakubu, the Desk Officer of the National Health Research Ethics Committee (NHREC), the committee in charge of health research ethics committee regulation in Nigeria, noted that the National Health Research Ethics Code is a well thought through document that can help significantly reduce research participants’ abuse. The document compliments the Good Clinical Practice document developed by NAFDAC also for clinical trial regulation. Between NAFDAC and NHREC, unethical research practices can be reduced to the barest minimum in Nigeria when all parties play their role as proscribed in the documents.

It is important to consider these potential as this meeting comes up on the heel of earlier consultative meetings held between community representative and researchers stakeholders in Nigeria in June, August and September this year. The consultative meetings were facilitated by NHVMAS in collaboration with four other partners (TIER, CADAM, IRMA, Safehaven). Community members were able to identify many research irregularities that affect the informed consent process, community engagement in research processes, and the standard of care provided for research participants. One major concern as expressed by community participants at this meeting is what often happens in many teaching hospitals: patients are made to pay for research related procedures. This is actually unethical but unfortunately, many patients are not aware of this right, noted Ms Florita Durueke, the Programme Manager of NHVMAS. NHVMAS is expending time and efforts at building capacity of members of the community to understand their rights, roles and responsibilities as research participants. We hope Nigerians will be able to learn and identify such abuses and start to speak up against these themselves, Ms Durueke commented.